An Anesthesia-Centered Bundle to Reduce Postoperative Pulmonary Complications: The PRIME-AIR Study
PRIME-AIR
3 other identifiers
interventional
794
1 country
16
Brief Summary
Postoperative pulmonary complications (PPCs) are a major cause of morbidity and mortality in surgical patients. National estimates suggest 1,062,000 PPCs per year, with 46,200 deaths, and 4.8 million additional days of hospitalization. The objective of the study is to develop and implement perioperative strategies to eliminate PPCs in abdominal surgery, the field with the largest absolute number of PPCs. We will conduct a randomized controlled pragmatic trial in 750 studied participants. The effectiveness of an individualized perioperative anesthesia-centered bundle will be compared to the usual anesthetic care in patients receiving open abdominal surgery. At the end of this project, the investigators expect to change clinical practice by establishing a new and clinically feasible anesthesia-centered strategy to reduce perioperative lung morbidity. The research will be conducted across 14 US academic centers, and will be funded by the National Institute of Health.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2020
Longer than P75 for not_applicable
16 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 26, 2019
CompletedFirst Posted
Study publicly available on registry
September 27, 2019
CompletedStudy Start
First participant enrolled
January 29, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 13, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 13, 2023
CompletedResults Posted
Study results publicly available
July 4, 2025
CompletedOctober 6, 2025
September 1, 2025
3.5 years
September 26, 2019
February 5, 2025
September 16, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Number and Severity of Postoperative Pulmonary Complications Between Participant Groups
The distribution of the number and severity of accumulated post-operative pulmonary complications (PPCs) between the control and intervention groups during the first 7 days after surgery.
Postoperative Days 0 through 7
Secondary Outcomes (12)
Number of Participants With Grade 1 and 2 Postoperative Pulmonary Complications
Postoperative Days 0 through 7
Number of Participants With Grade 3 and 4 Postoperative Pulmonary Complications
Postoperative Days 7, 30, and 90
Number of Participants With Hypoxemia by Postoperative Day 7
Postoperative Days 0 through 7
Number of Participants With Atelectasis by Postoperative Day 7
Days 0 through 7 after the day of surgery
Number of Participants With Pneumonia (Suspected and Proved) by Postoperative Day 7
Days 0 through 7
- +7 more secondary outcomes
Study Arms (2)
Usual Care
NO INTERVENTIONParticipants in this arm will receive usual anesthetic and postoperative care as provided in each site.
Intervention
EXPERIMENTALThis arm will receive the bundle of interventions.
Interventions
Brochure and video about relevance of postoperative pulmonary complications, postoperative mobilization and use of incentive spirometry.
PEEP will be set by maximizing respiratory system compliance along a decremental PEEP titration following an incremental recruitment maneuver.
Administration of neuromuscular blocking agents and their reversal will be done based on established protocol.
Participants will be encouraged to adhere to incentive spirometry to be started 2 hours after surgery and maintained until participant freely ambulates. Supervision will be provided 3 times/day for continuous education and management of barriers to optimal performance.
Participants will be encouraged to adhere to prescription of early ambulation.
Eligibility Criteria
You may qualify if:
- Adults (\>=18 years) scheduled for elective surgery with expected duration \>=2 hours
- Open abdominal surgery including: gastric, biliary, pancreatic, hepatic, major bowel, ovarian, renal tract, bladder, prostatic, radical hysterectomy, and pelvic exenteration
- Intermediate or high risk of PPCs defined by an ARISCAT (Assess Respiratory Risk in Surgical Patients in Catalonia Score) risk score\>=26
You may not qualify if:
- Inability or refusal to provide consent
- Inability or significant difficulty to perform any study interventions, including incentive spirometry, ambulation and/or maintaining follow-up contact with study personnel for up to 90 days after the date of surgery.
- Participation in any interventional research study within 30 days of the time of the study.
- Previous surgery within 30 days prior to this study.
- Pregnancy
- Emergency surgery
- Severe obesity (above Class I, BMI\>=35 kg/m2)
- Significant lung disease: any diagnosed or treated respiratory condition that (a) requires home oxygen therapy or non-invasive ventilation (except nocturnal treatment of sleep apnea without supplemental oxygen), (b) severely limits exercise tolerance to \<4 metabolic equivalents (METs) (e.g., patients unable to do light housework, walk flat at 4 miles/h or climb one flight of stairs), (c) required previous lung surgery, or (d) includes presence of severe pulmonary emphysema or bullae
- Significant heart disease: cardiac conditions that limit exercise tolerance to \<4 METs
- Renal failure: peritoneal or hemodialysis requirement or preoperative creatinine \>=2 mg/dL
- Neuromuscular disease that impairs ability to ventilate without assistance
- Severe chronic liver disease (Child-Turcotte-Pugh Score \>9, Appendix I)
- Sepsis
- Malignancy or other irreversible condition for which 6-month mortality is estimated \>=20%
- Bone marrow transplant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (16)
University of California - San Francisco
San Francisco, California, 94115, United States
Stanford University
Stanford, California, 94305, United States
University of Colorado, Anschutz Medical Campus
Aurora, Colorado, 80045, United States
South Florida Veterans Affairs Foundation for Research and Education, Inc.
Miami, Florida, 33125, United States
Northwestern University
Evanston, Illinois, 60208, United States
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Beth Israel Deaconess Hospital
Boston, Massachusetts, 02215, United States
Univerisity of Massachusetts Amherst Center
Worcester, Massachusetts, 01655, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Columbia University Medical Center
New York, New York, 10032, United States
Memorial Sloan Kettering
New York, New York, 10065, United States
University of Rochester
Rochester, New York, 14642, United States
Montefiore Hospital
The Bronx, New York, 10467, United States
Duke University
Durham, North Carolina, 27710, United States
Related Publications (11)
PROVE Network Investigators for the Clinical Trial Network of the European Society of Anaesthesiology; Hemmes SN, Gama de Abreu M, Pelosi P, Schultz MJ. High versus low positive end-expiratory pressure during general anaesthesia for open abdominal surgery (PROVHILO trial): a multicentre randomised controlled trial. Lancet. 2014 Aug 9;384(9942):495-503. doi: 10.1016/S0140-6736(14)60416-5. Epub 2014 Jun 2.
PMID: 24894577BACKGROUNDWriting Committee for the PROBESE Collaborative Group of the PROtective VEntilation Network (PROVEnet) for the Clinical Trial Network of the European Society of Anaesthesiology; Bluth T, Serpa Neto A, Schultz MJ, Pelosi P, Gama de Abreu M; PROBESE Collaborative Group; Bluth T, Bobek I, Canet JC, Cinnella G, de Baerdemaeker L, Gama de Abreu M, Gregoretti C, Hedenstierna G, Hemmes SNT, Hiesmayr M, Hollmann MW, Jaber S, Laffey J, Licker MJ, Markstaller K, Matot I, Mills GH, Mulier JP, Pelosi P, Putensen C, Rossaint R, Schmitt J, Schultz MJ, Senturk M, Serpa Neto A, Severgnini P, Sprung J, Vidal Melo MF, Wrigge H. Effect of Intraoperative High Positive End-Expiratory Pressure (PEEP) With Recruitment Maneuvers vs Low PEEP on Postoperative Pulmonary Complications in Obese Patients: A Randomized Clinical Trial. JAMA. 2019 Jun 18;321(23):2292-2305. doi: 10.1001/jama.2019.7505.
PMID: 31157366BACKGROUNDWilliams EC, Motta-Ribeiro GC, Vidal Melo MF. Driving Pressure and Transpulmonary Pressure: How Do We Guide Safe Mechanical Ventilation? Anesthesiology. 2019 Jul;131(1):155-163. doi: 10.1097/ALN.0000000000002731.
PMID: 31094753BACKGROUNDLadha K, Vidal Melo MF, McLean DJ, Wanderer JP, Grabitz SD, Kurth T, Eikermann M. Intraoperative protective mechanical ventilation and risk of postoperative respiratory complications: hospital based registry study. BMJ. 2015 Jul 14;351:h3646. doi: 10.1136/bmj.h3646.
PMID: 26174419BACKGROUNDWanderer JP, Ehrenfeld JM, Epstein RH, Kor DJ, Bartz RR, Fernandez-Bustamante A, Vidal Melo MF, Blum JM. Temporal trends and current practice patterns for intraoperative ventilation at U.S. academic medical centers: a retrospective study. BMC Anesthesiol. 2015 Mar 28;15:40. doi: 10.1186/s12871-015-0010-3. eCollection 2015.
PMID: 25852301BACKGROUNDde Jong MAC, Ladha KS, Vidal Melo MF, Staehr-Rye AK, Bittner EA, Kurth T, Eikermann M. Differential Effects of Intraoperative Positive End-expiratory Pressure (PEEP) on Respiratory Outcome in Major Abdominal Surgery Versus Craniotomy. Ann Surg. 2016 Aug;264(2):362-369. doi: 10.1097/SLA.0000000000001499.
PMID: 26496082BACKGROUNDFutier E, Constantin JM, Paugam-Burtz C, Pascal J, Eurin M, Neuschwander A, Marret E, Beaussier M, Gutton C, Lefrant JY, Allaouchiche B, Verzilli D, Leone M, De Jong A, Bazin JE, Pereira B, Jaber S; IMPROVE Study Group. A trial of intraoperative low-tidal-volume ventilation in abdominal surgery. N Engl J Med. 2013 Aug 1;369(5):428-37. doi: 10.1056/NEJMoa1301082.
PMID: 23902482BACKGROUNDFerrando C, Soro M, Unzueta C, Suarez-Sipmann F, Canet J, Librero J, Pozo N, Peiro S, Llombart A, Leon I, India I, Aldecoa C, Diaz-Cambronero O, Pestana D, Redondo FJ, Garutti I, Balust J, Garcia JI, Ibanez M, Granell M, Rodriguez A, Gallego L, de la Matta M, Gonzalez R, Brunelli A, Garcia J, Rovira L, Barrios F, Torres V, Hernandez S, Gracia E, Gine M, Garcia M, Garcia N, Miguel L, Sanchez S, Pineiro P, Pujol R, Garcia-Del-Valle S, Valdivia J, Hernandez MJ, Padron O, Colas A, Puig J, Azparren G, Tusman G, Villar J, Belda J; Individualized PeRioperative Open-lung VEntilation (iPROVE) Network. Individualised perioperative open-lung approach versus standard protective ventilation in abdominal surgery (iPROVE): a randomised controlled trial. Lancet Respir Med. 2018 Mar;6(3):193-203. doi: 10.1016/S2213-2600(18)30024-9. Epub 2018 Jan 19.
PMID: 29371130BACKGROUNDBrandao JC, Lessa MA, Motta-Ribeiro G, Hashimoto S, Paula LF, Torsani V, Le L, Bao X, Eikermann M, Dahl DM, Deng H, Tabatabaei S, Amato MBP, Vidal Melo MF. Global and Regional Respiratory Mechanics During Robotic-Assisted Laparoscopic Surgery: A Randomized Study. Anesth Analg. 2019 Dec;129(6):1564-1573. doi: 10.1213/ANE.0000000000004289.
PMID: 31743177BACKGROUNDFernandez-Bustamante A, Parker RA, Frendl G, Lee JW, Nagrebetsky A, Grecu L, Amar D, Tanaka P, Sprung J, Gupta RA, Subramanian B, Giquel J, Eikermann M, Musch G, Nadler JW, Gama de Abreu M, Bartels K, Grover M, Chen LL, Sparling J, Douin DJ, Weingarten T, Wagener G, Thompson BT, Vidal Melo MF; Perioperative Research Network (PRN) Investigators. Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2025 May;13(5):447-459. doi: 10.1016/S2213-2600(25)00040-2. Epub 2025 Feb 25.
PMID: 40020692DERIVEDFernandez-Bustamante A, Parker RA, Sprung J, Eikermann M, Gama de Abreu M, Ferrando C, Thompson BT, Vidal Melo MF. An anesthesia-centered bundle to reduce postoperative pulmonary complications: The PRIME-AIR study protocol. PLoS One. 2023 Apr 6;18(4):e0283748. doi: 10.1371/journal.pone.0283748. eCollection 2023.
PMID: 37023031DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Marcos F. Vidal Melo
- Organization
- Columbia University Medical Center
Study Officials
- PRINCIPAL INVESTIGATOR
Marcos F Vidal Melo, MD
Columbia University
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 26, 2019
First Posted
September 27, 2019
Study Start
January 29, 2020
Primary Completion
July 13, 2023
Study Completion
July 13, 2023
Last Updated
October 6, 2025
Results First Posted
July 4, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- After conclusion of the study, planned for 5 years.
- Access Criteria
- According to the NIH/NHLBI access policies.
In compliance with with the NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information (Notice Number NOT-OD-16-149) and NIH/NHLBI guidelines, we will submit data and specimens to the NHLBI BioLINCC (The Biologic Specimen and Data Repository Information Coordinating Center) repository, and follow procedures specified in the BioLINCC Handbook. First, list of materials to be submitted including the specimens for the NHLBI biorepository will be created. Then a data redaction plan removing personal identifiers and administrative data will be prepared, recoding low-frequency data values for subject privacy protection. The data set documentation, summary of changes made during redaction, and a summary report will be submitted to the BioLINCC repository following the standard procedures. We will comply with any modifications identified during the BioLINCC repository review, and submit the final material acceptable to the repository.